ARA-C (total dose 6 mg/kg). This treatment was repeated three weeks later and he had passed into full remission by January 1971. Remission was maintained by weekly immunotherapy with B.C.G. and allogeneic leukaemia cells and monthly courses of chemotherapy. The chemotherapy consisted of five daily injections of ARA-C 1.2 mg/kg together with either a single injection of daunorubicin 1.5 mg/kg or 6-thioguanine 2 mg/kg per day for five days. After four such courses he developed burning sensations in his feet which followed each subsequent course of treatment but gradually improved between courses. Because this occurred after every course it could be related only to the ARA-C. Chemotherapy was stopped on 26 November 1971 after a total dose of 7 g of ARA-C, but he continued to complain of intermittent burning or tingling sensations in his feet, sometimes extending in a stocking distribution to below the knee and occasionally affecting the fingers. There has never been any objective neurological abnormality and his symptoms have continued to improve slowly, but they are still present 2½ years after stopping chemotherapy.

Case 2—A 52-year-old man with acute myelogenous leukaemia (weight 70 kg) had similar induction chemotherapy to Case 1 and after 600 mg of ARA-C he complained of numbness and paraesthesiae involving all four limbs. After four courses of treatment he passed into full haematological remission and was then given eight weeks' treatment with 6-thioguanine and cyclophosphamide. This was immediately followed by a single injection of daunorubicin 100 mg and ARA-C 130 mg. He then stopped all chemotherapy and was maintained in complete remission on immunotherapy alone. During this period his neurological symptoms improved, though he still complained of painful intermittent paraesthesiae in a glove-and-stocking distribution extending to the elbows and knees and intermittent stabbing pains throughout the body. He relapsed after seven months of immunotherapy and was treated with two courses of high-dose ARA-C (total 20 mg/kg) followed by a single intravenous injection of adriamycin (2 mg/kg). These courses were given 10 days apart and following the second course his paraesthesiae became worse. Thereafter aggravation of his neurological symptoms was always associated with ARA-C. A second complete remission lasted only three months in spite of monthly courses of ARA-C 2 mg/kg for five days and 6-thioguanine alternating with daunorubicin. Reinduction chemotherapy included ARA-C (180 mg/daily for five days), following which his neurological symptoms rapidly became worse and their character changed. He continued to have numbness extending up to the elbows and knees and tingling sensations in the fingers, but he also had burning or aching pains with the same distribution. At no time during the course of his illness had there been any objective neurological abnormalities. He died five months after the start of his second relapse.

Both of these patients had symptoms characteristic of a sensory peripheral neuropathy which developed during cytotoxic therapy for acute myelogenous leukaemia. In both cases the only drug consistently related with deterioration of the neurological symptoms was ARA-C. Case 1 would appear to have developed these symptoms after a total of 4 g of ARA-C, but because of their subjective nature the time of onset was difficult to determine precisely. Case 2 developed his neurological symptoms after a total dose of 600 mg of ARA-C. Both patients reported improvement in the absence of chemotherapy, but Case 1 still experiences some paraesthesiae two and a half years after his last dose of ARA-C.

During the past six years at least 350 new adult patients with leukaemia have been treated with ARA-C in our departments, of whom approximately 40% have had maintenance ARA-C after remission. This means that the incidence of problems due to this particular complication is very low. Nevertheless, there is no question that the quality of life was impaired considerably in both the patients reported here by their neurological symptoms. We would be most interested to know if other workers who use this drug frequently have noticed a similar association.

We wish to thank Dr. T. McElwain for permission to publish the second case report.

—We are, etc.,

J. A. RUSSELL

Immunotherapy Department,
Royal Marsden Hospital,
Sutton, Surrey

R. L. POWLES

I.C.R.F. Department of Medical Oncology,
St. Bartholomew's Hospital,
London E.C.1

¹ Weiss, H. D., Walker, M. D., and Wiernik, P. H.,
New England Journal of Medicine, 1974, **291**,
75 and 127.

Cutaneous and Ocular Reactions to Practolol

SIR,—I was very interested to read the paper by Dr. R. H. Felix and others (9 November, p. 321). I would like to bring up to date a quotation from a publication of mine¹ which appeared in their discussion section.

I reported an incidence of 3–4% of positive antinuclear factor (A.N.F.) titre in patients on practolol, but in a retrospective survey of 67 patients taking practolol for angina we found that seven had an A.N.F. titre greater than 1/40, an incidence of 11%. In a prospective survey of 71 patients who were treated with practolol for angina or dysrhythmias the A.N.F. titre was greater than 1/40 before treatment in only one (1.4%). After an average of six months of treatment this had risen to five (11%) and one of these patients developed a florid disseminated lupus erythematosus (D.L.E.).

A prospective study of 50 patients receiving oxprenolol for the treatment of hypertension revealed no instance of a raised A.N.F. titre before or after treatment for a period of three months. The same was true for 24 patients taking propranolol for hypertension. There have been no instances of D.L.E. syndrome in these two groups of patients.

These observations suggest that practolol is unique among the commonly used beta-blocking agents in producing the D.L.E. syndrome and in producing a rising A.N.F. titre.—I am, etc.,

E. B. RAFTERY

Northwick Park Hospital,
Harrow, Middlesex

¹ Raftery, E. B., in *New Perspectives in Beta-blockade International Symposium*, p. 239.
Denmark: Ciba Laboratories, 1972.

Ischaemic Heart Disease in Young Women

SIR,—In his analysis of ischaemic heart disease in young women Dr. M. F. Oliver (2 November, p. 253) claims that there had been a hypertensive "risk factor" in 40% of those who suffered myocardial infarction. This figure, I would suggest, is misleading since the evidence, much of it retrospective, is insufficient to establish that these women were hypertensive before their infarctions.

An unstated proportion of them were "recorded as having hypertension" for no better reason than that they had been under treatment for this condition apparently at the hands of their family doctor, there being no reference to any earlier attendance in Dr. Oliver's department. In others the diagnosis was made on the strength of a clinic finding of a diastolic pressure that remained at a level of 100 mm Hg or more during a period of ten minutes rest on one occasion. A single

such reading in women aged up to 45 may suggest but cannot justify a diagnosis of hypertension. Still less is it relevant that in the remainder of this group the pressure was found to have risen into similar levels within a year after the infarction.

It is said of the allegedly hypertensive patients who sustained infarcts that 25% also had left ventricular hypertrophy, the implication being that here was further proof of pre-existing hypertension. We are not told how the hypertrophy was recognized. But in patients who had survived, or were about to suffer, infarction the assumption would appear to be precariously based. Radiologically it is seldom possible to make an exact distinction between minor cardiac enlargement caused by hypertension and that also found in normotensive patients with myocardial change secondary to coronary artery disease. Nor do electrocardiographic tracings afford any precise means of distinguishing between the two, especially in terms of S-T depression and T inversion, the only abnormalities that are cited.

That hypertension after infarction was later found to be a "potent risk factor" is scarcely surprising since it was imposing strain upon a myocardium that was already damaged, a simple sequence of cause and effect unrelated to those obscure and diverse influences that determine the slow development of coronary atheroma together with its allied, yet nonetheless distinct, occasional complication of myocardial infarction.—I am, etc.,

I. MCD. G. STEWART

Victoria Hospital,
Blackpool

Impaired Colour Vision in Diagnosis of Digitalis Intoxication

SIR,—Measurement of the serum level of digoxin provides an accurate estimate of the diagnosis of digitalis intoxication.^{1,2} Measurements are, however, time-consuming and need expensive instrumentation. Simple methods for the confirmation of digitalis intoxication would be welcome.

Various visual complaints are frequently seen as initial signs of digitalis toxicity.^{3,4} We have tested colour vision in five consecutive ambulant patients in whom the suspicion of digitalis intoxication arose because of clinical signs like loss of appetite, nausea, abdominal discomfort, extrasystoles, or unexplained feeling of sickness. In two patients barium meal examination, carried out because of loss of weight and constant abdominal discomfort, had revealed no signs of organic disease. In the examination of colour vision Ishihara tables (24 plates, 1974) were used. The patients (two male, three female, aged 61–78) were receiving 0.15 to 0.75 mg of digoxin daily and two with heart failure were also receiving frusemide with potassium chloride; four had atrial fibrillation. The serum potassium level was normal (4.2–4.6 mmol/l) in all five. The serum digoxin was only 1.3 ng/ml in one patient but ranged from 2.1 to 3.2 ng/ml in the other four.

When first studied all five patients had some degree of difficulty in seeing the plates for red-green vision. All also complained of indistinct vision of objects. When the test was repeated two weeks after diminishing the digoxin dose none of the subjects had